Cite
APA Citation
Tsujikawa, L., Kulikowski, E., Calosing, C., Wasiak, S., Gilham, D., Halliday, C., Johansson, J., Sweeney, M., & Wong, N. (2018). apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells. Atherosclerosis, 32, 104–. http://access.bl.uk/ark:/81055/vdc_100066061881.0x000011